Back to home

Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report

Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report

JERUSALEM--(BUSINESS WIRE)--Jul. 17, 2018-- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its annual social impact report, highlighting achievements related to the two pillars that drive the Company’s initiatives: building healthy communities and leading a responsible business.

Teva’s 2017 Social Impact Report spotlights the company’s commitment to corporate responsibility and transparency, and provides context on its efforts to contribute to healthy communities in ways the business can uniquely support—through safe medicines, collaboration, health initiatives and innovative research. The report also presents six new corporate positions and policies, establishing the company’s commitment to donations, human rights, diversity and inclusion, occupational health and safety, the environment and antimicrobial resistance.


About Teva

Teva is among the top 15 global pharmaceutical companies globally, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 60 markets every day. Teva produces a leading innovative treatment for multiple sclerosis and has late-stage development programs for a range of disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions.

With its European headquarters in Amsterdam, the Netherlands, Teva is also the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a broad range of products in nearly every therapeutic area. Teva draws on its specialty and generics capabilities to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2017 were $22.4 billion. For more information, visit http://www.tevaeurope.com/news.

PR Contacts:

Fiona Cohen 

Amsterdam

+31 620 08 25 45